Hani Kushlaf, MD, an Associate Professor of Neurology and Pathology at the University of Cincinnati, discusses results from the phase 3 COMET trial. This 49-week study was designed to investigate the effect of avalglucosidase alfa on respiratory muscle strength in patients with late-onset Pompe disease. Compared with alglucosidase alfa, the only approved enzyme replacement therapy, treatment with avalglucosidase alfa was noninferior in terms of the percent predicted forced vital capacity. Dr Kushlaf notes that fewer participants receiving avalglucosidase alfa reported adverse events.